【摘要】 目的评价莫西沙星、阿米卡星、对氨基水杨酸异烟肼、丙硫异烟胺、吡嗪酰胺、克拉霉素联合治疗耐多药肺结核的近期疗效。方法 34例耐多药肺结核患者随机分为治疗组和对照组,两组予不同的化疗方案治疗。结果经过6个月的治疗,治疗组的痰菌阴转情况为88.8%,病灶吸收情况为72.2%,症状改善情况为87.5%。对照组的痰菌阴转情况为62.5%,病灶吸收情况为56.2%,症状改善情况为50.0%。治疗组明显优于对照组,差异具有统计学意义(P<0.05)。结论莫西沙星、阿米卡星、对氨基水杨酸异烟肼联合丙硫异烟胺、吡嗪酰胺、克拉霉素联合治疗耐多药肺结核方案优于卷曲霉素、左氧氟沙星、对氨基水杨酸异烟肼联合丙硫异烟胺、吡嗪酰胺、阿莫西林/克拉维酸联合治疗耐多药肺结核方案。更多还原

【Abstract】 Objective To evaluate the short-term effect of moxifloxacin, amikacin, pasiniazid, ethionamide, pyrazinamide, clarithromycin combined in treatment of multi drug resistant pulmonary tuberculosis. Methods A total of 34 patients with multi drug resistant pulmonary tuberculosis were randomly divided into treatment group and control group, two groups received chemotherapy in different treatment. Results After 6 months of treatment, the sputum negative conversion of the treatment group was 88.8%, the focus absorption was 72.2%, the improvement of the symptoms was 87.5%. The sputum negative conversion of control group was 62.5%, the focus absorption was 56.2%, the improvement of the symptoms was 50.0%. The treatment group was significantly better than the control group,the difference was statistically significant(P<0.05). Conclusion Moxifloxacin,amikacin, using para aminosalicylic acid, ethionamide, pyrazinamide,combined clarithromycin in treatment of multi drug resistant pulmonary tuberculosis is better than that of capreomycin, levofloxacin, using para aminosalicylic acid,ethionamide, pyrazinamide,a combination moxilin/clavulanic acid in treatment of multi drug resistant pulmonary.更多还原